目的:对辅助内分泌治疗(AET)的依从性欠佳,并探索了一系列变量,以了解患者服药的经历和动机。然而,肿瘤学家对依从性的看法知之甚少。这项研究的目的是探讨肿瘤学家对依从性/非依从性的看法及其策略,以确保患者继续接受治疗,以告知潜在的可修改干预措施的发展。
方法:定性研究使用深入,在阿根廷对16名肿瘤学家进行了半结构化访谈.分层目的性抽样用于从3个健康子系统(私人,社会保障,和公共)。使用框架方法分析数据。
结果:肿瘤学家认为,与化疗相比,患者的依从性总体较高,并且与AET的良好耐受性相关。提供的信息,患者感到放心(害怕复发)。不遵守被认为不是一个主要问题,这与罕见的严重副作用有关,年轻的年龄,拒绝治疗,失去保险计划,缺乏教育,和社会环境。患者对令人讨厌的副作用的抱怨并未被确定为停药的主要原因。公共和私营部门的患者,然而,被认为对副作用有不同的态度。管理策略包括医学变革,转介支持服务,和肿瘤学家的支持关系。
结论:肿瘤学家对AET依从性/非依从性的观点与文献中基于患者报告因素的观点显示出相似性和显著差异。总体依从性被认为是高的,但在公共部门患者中,非故意不依从的可能性似乎很重要.向患者提供的信息应针对严重和令人不快的副作用提供明确的解释。应考虑采取干预措施来提高肿瘤学家和负责生存护理的专家的沟通技巧,以增强患者的自我效能和有效的服药。需要关于依从性的可靠数据。
OBJECTIVE: Adherence to adjuvant endocrine therapy (AET) is suboptimal, and a range of variables have been explored for understanding patients\' experiences and motivations for medication-taking. However, oncologists\' views on adherence are poorly understood. The aim of this study was to explore oncologists\' perspectives on adherence/non-adherence and their strategies to ensure patients continue with treatments to inform the development of potential modifiable interventions.
METHODS: A qualitative study using in-depth, semi-structured interviews with 16 oncologists was conducted in Argentina. A stratified purposive sampling was used to recruit female and male participants from 3 health subsystems (private, social security, and public). Data were analyzed using the Framework approach.
RESULTS: Oncologists believed patients\' adherence was overall high and associated it with good tolerance of AET in comparison to chemotherapy, information provided, and patients feeling reassured (fear of recurrence). Non-adherence was not perceived as a major source of concern, and it was related to rare cases of severe side effects, young age, refusing treatment, losing the insurance plan, lack of education, and social circumstances. Patients\' complaints of bothersome side effects were not identified as a main reason to discontinuation. Public and private sector patients, however, were perceived as having different attitudes toward side effects. Management strategies included medicine change, referral to support services, and a supportive relationship with the oncologist.
CONCLUSIONS: Oncologists\' perspectives on adherence/non-adherence to AET show similarities and significant differences with those in the literature based on patient-reported factors. Overall adherence was considered high, but the likelihood of unintentional non-adherence seems important in public sector patients. Information to patients should provide clear explanations on both severe and unpleasant side effects. Interventions to improve communication skills in oncologists and specialists responsible for survivorship care should be considered to strengthen patients\' self-efficacy and effective medication-taking. Reliable data on adherence are needed.